Pharmacology
Pharmacology
Innovative technology in the delivery of leuprolide acetate
Fensolvi® (leuprolide acetate) for injectable suspension is the first and only 6-month, subcutaneous injection of leuprolide acetate for CPP. It uses a biodegradable in situ gel delivery system, which contains a unique co-polymer of DL-lactide-co-glycolide, dissolved in N-methyl-2-pyrrolidone. After injection, the polymeric gel suspension delivery system forms an in-situ solid, enabling sustained and controlled extended-release of leuprolide acetate as it safely biodegrades. [1]
Subcutaneous injection benefits
SC injections provide benefits for health care providers and patients [2]
- Short needle
- Low risk of hitting bones or nerves
- Lack of reliance on muscle mass
- Provides a wider range of injection site options
References
- Fensolvi® (leuprolide acetate) for injectable suspension 45 mg Prescribing Information. Dublin 2, Ireland: Tolmar International, Ltd.; 2020.
- Prettyman, J., Engel, L., Boldt-Houle, D.M., Atkinson, S., & Wilt, W. (2018). Personalizing treatment in the delivery of care by nurses to patients with prostate cancer. Urologic Nursing, 39(2), 83-99. doi:10.7257/1053- 816X.2019.2.83